$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000158364818000032 Filed on May 10, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$11.69M	$4.152M	$1.343M
YoY Change	530.92%	209.16%	7.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.780M	$4.350M	$3.990M
YoY Change	9.89%	9.02%	102.54%
% of Gross Profit
Research & Development	$9.155M	$7.936M	$5.360M
YoY Change	69.66%	48.06%	46.47%
% of Gross Profit
Depreciation & Amortization	$150.0K	$134.0K	$100.0K
YoY Change	36.36%	34.0%	5.8%
% of Gross Profit
Operating Expenses	$13.93M	$12.29M	$9.349M
YoY Change	43.0%	31.44%	66.14%
Operating Profit	-$2.243M	-$8.136M	-$8.006M
YoY Change	-71.58%	1.62%	82.76%
Interest Expense	$662.0K	$325.0K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.230M	-$903.0K	$12.00K
YoY Change	-189.13%	-7625.0%	-94.54%
Pretax Income	-$351.0K	-$8.714M	-$7.994M
YoY Change	-96.21%	9.01%	92.11%
Income Tax	-$148.0K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$203.0K	-$8.714M	-$7.994M
YoY Change	-97.99%	9.01%	92.11%
Net Earnings / Revenue	-1.74%	-209.87%	-595.23%
Basic Earnings Per Share
Diluted Earnings Per Share	-$3.705K	-$174.0K	-$185.6K
COMMON SHARES
Basic Shares Outstanding	53.97M shares	53.86M shares	43.06M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$151.0M	$159.6M	$55.20M
YoY Change	200.2%	189.13%	76.92%
Cash & Equivalents	$50.58M	$109.5M	$55.24M
Short-Term Investments	$100.4M	$50.10M
Other Short-Term Assets	$3.100M	$3.200M	$3.500M
YoY Change	-20.51%	-8.57%	-2.78%
Inventory
Prepaid Expenses
Receivables	$2.559M	$3.309M	$39.01K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$156.6M	$166.1M	$58.76M
YoY Change	52.42%	182.66%	68.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.597M	$4.445M	$2.993M
YoY Change	49.01%	48.51%	35.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$700.0K	$2.600M
YoY Change
Other Assets	$129.0K	$130.0K	$126.2K
YoY Change	0.62%	3.02%	-1.43%
Total Long-Term Assets	$5.426M	$7.158M	$3.119M
YoY Change	68.86%	129.48%	33.39%
TOTAL ASSETS
Total Short-Term Assets	$156.6M	$166.1M	$58.76M
Total Long-Term Assets	$5.426M	$7.158M	$3.119M
Total Assets	$162.0M	$173.2M	$61.88M
YoY Change	52.92%	179.98%	66.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.174M	$1.934M	$3.317M
YoY Change	-31.69%	-41.7%	95.12%
Accrued Expenses	$4.562M	$6.578M	$2.959M
YoY Change	-28.17%	122.31%	27.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$52.33M	$54.76M	$11.44M
YoY Change	46.2%	378.5%	76.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$37.00K	$37.00K	$42.09K
YoY Change	-13.68%	-12.08%	5.9%
Total Long-Term Liabilities	$37.00K	$37.00K	$42.09K
YoY Change	-13.68%	-12.08%	5.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$52.33M	$54.76M	$11.44M
Total Long-Term Liabilities	$37.00K	$37.00K	$42.09K
Total Liabilities	$106.7M	$122.5M	$43.84M
YoY Change	10.44%	179.53%	337.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$129.2M	-$129.0M	-$110.7M
YoY Change	7.03%	16.6%	31.69%
Common Stock	$187.1M	$185.7M	$130.1M
YoY Change	41.58%	42.68%	15.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$55.32M	$50.69M	$18.04M
YoY Change
Total Liabilities & Shareholders Equity	$162.0M	$173.2M	$61.88M
YoY Change	52.92%	179.98%	66.31%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$203.0K	-$8.714M	-$7.994M
YoY Change	-97.99%	9.01%	92.11%
Depreciation, Depletion And Amortization	$150.0K	$134.0K	$100.0K
YoY Change	36.36%	34.0%	5.8%
Cash From Operating Activities	-$8.990M	$31.34M	$25.77M
YoY Change	37.88%	21.61%	1169.46%
INVESTING ACTIVITIES
Capital Expenditures	-$400.0K	$414.0K	$179.0K
YoY Change	-40.3%	131.28%	163.55%
Acquisitions
YoY Change
Other Investing Activities	-$48.37M	-$7.880M
YoY Change	-483800.0%
Cash From Investing Activities	-$48.77M	-$8.293M	-$180.0K
YoY Change	7289.39%	4507.22%	157.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$47.21M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	70.00K	$48.16M	0.000
YoY Change	-95.21%
NET CHANGE
Cash From Operating Activities	-8.990M	$31.34M	25.77M
Cash From Investing Activities	-48.77M	-$8.293M	-180.0K
Cash From Financing Activities	70.00K	$48.16M	0.000
Net Change In Cash	-57.69M	$71.64M	25.59M
YoY Change	908.57%	179.96%	1205.61%
FREE CASH FLOW
Cash From Operating Activities	-$8.990M	$31.34M	$25.77M
Capital Expenditures	-$400.0K	$414.0K	$179.0K
Free Cash Flow	-$8.590M	$30.93M	$25.59M
YoY Change	46.84%	20.84%	1204.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53974184	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
CY2018Q1	dei	Trading Symbol TradingSymbol	PIRS
CY2017Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	791000	USD
CY2018Q1	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	778000	USD
CY2017Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	424000	USD
CY2018Q1	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	402000	USD
CY2018Q1	pirs	Cash Cash Equivalents And Investments CashCashEquivalentsAndInvestments	162200000	USD
CY2017Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	62851000	USD
CY2018Q1	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	146483000	USD
CY2018Q1	pirs	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-200000	USD
CY2017Q1	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	613000	USD
CY2018Q1	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	65000	USD
CY2017	pirs	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Income Tax Expense Benefit Before Valuation Allowance Impact TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateIncomeTaxExpenseBenefitBeforeValuationAllowanceImpact	-3700000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2879000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3207000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4695000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5973000	USD
CY2017Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6170000	USD
CY2018Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6578000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2452000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1934000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15546000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3309000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6170000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6578000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1322000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1663000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	136484000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	185638000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11200000	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14700000	shares
CY2017Q4	us-gaap	Assets Assets	103876000	USD
CY2018Q1	us-gaap	Assets Assets	173239000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	89790000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	166081000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1363000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	53993000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52643000	USD
CY2017Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29356000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55242000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37878000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109521000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	25886000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	71643000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45017062	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53974184	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45017062	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53974184	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	45000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	54000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7943000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9992000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2325000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1210000	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	295000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	438000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	37153000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	46251000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	46542000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	67746000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	134000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3989000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4352000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7994000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8714000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-32912000	USD
CY2018Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-38907000	USD
CY2017Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2018Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	325000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	92354000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	122546000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103876000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	173239000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45775000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	54763000	USD
CY2017Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1008000	USD
CY2018Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	3444000	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	9922000	USD
CY2018Q1	us-gaap	Long Term Investments LongTermInvestments	2583000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	0	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	48159000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-179000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-8293000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	25771000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	31339000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-7994000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-8714000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	9349000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	12288000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8006000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8136000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1308000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2525000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	51000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-747000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-531000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37000	USD
CY2017Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2018Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	12000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-903000	USD
CY2017Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2018Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	91000	USD
CY2018Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	USD
CY2017Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2018Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	11479000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	179000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	414000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4963	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2907	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4963	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2907	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1615000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3190000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47207000	USD
CY2017Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
CY2018Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	3600000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	826000	USD
CY2017Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	126000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6913000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7652000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4034000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4445000	USD
CY2017Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	335000	USD
CY2018Q1	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	617000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5360000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7936000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120312000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129026000	USD
CY2017Q1	us-gaap	Revenues Revenues	1343000	USD
CY2018Q1	us-gaap	Revenues Revenues	4152000	USD
CY2018Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.00
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	752000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1004000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	34751000	USD
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	50061000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	11522000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	50693000	USD
CY2017Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2018Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-697000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43064000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50046000	shares
CY2018Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of Credit Risk and Off-Balance Sheet Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no financial instruments with off‑balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments, and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts, at times, may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments, and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001583648-18-000032-index-headers.html	Edgar Link	pending
0001583648-18-000032-index.html	Edgar Link	pending
0001583648-18-000032.txt	Edgar Link	pending
0001583648-18-000032-xbrl.zip	Edgar Link	pending
a18050320181q10qexhibit101.htm	Edgar Link	pending
a18050320181q10qexhibit102.htm	Edgar Link	pending
exhibit311.htm	Edgar Link	pending
exhibit312.htm	Edgar Link	pending
exhibit321.htm	Edgar Link	pending
exhibit322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pirs-20180331.xml	Edgar Link	completed
pirs-20180331.xsd	Edgar Link	pending
pirs-20180331_cal.xml	Edgar Link	unprocessable
pirs-20180331_def.xml	Edgar Link	unprocessable
pirs-20180331_lab.xml	Edgar Link	unprocessable
pirs-20180331_pre.xml	Edgar Link	unprocessable
pirs3-31x201810xq.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs

2018 Q2 Form 10-Q Financial Statement

#000158364818000032 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS PIERIS PHARMACEUTICALS, INC. Stock $pirs

2018 Q2 Form 10-Q Financial Statement

#000158364818000032 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
PIERIS PHARMACEUTICALS, INC. Stock $pirs